2U3
vs
D
DAX Index
2U3
Over the past 12 months, 2U3 has outperformed DAX Index, delivering a return of +24% compared to the DAX Index's +12% growth.
Stocks Performance
2U3 vs DAX Index
Performance Gap
2U3 vs DAX Index
Performance By Year
2U3 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Alcon AG
Glance View
Alcon AG, headquartered in Geneva, Switzerland, emerges as a global leader in eye care, having spun off from Novartis in 2019 to operate independently. The company traces its roots back to a small pharmacy established in Fort Worth, Texas, in 1945, gradually expanding under the strategic vision of its founders. Today, Alcon stands at the intersection of innovation and necessity, catering to a world increasingly aware of eye health. The firm specializes in two main sectors: Surgical and Vision Care. In the Surgical division, Alcon offers advanced technologies and devices for ophthalmic surgery, encompassing cataract, retinal, and refractive procedures. Through these innovations, Alcon not only enhances patient outcomes but also streamlines operations for eye care professionals, carving out a significant market share in surgical solutions. Meanwhile, the Vision Care segment thrives by addressing the burgeoning demand for contact lenses and ocular health products. Alcon’s portfolio features daily disposable and reusable lenses, supported by innovative technologies that prioritize comfort and clarity of vision. Additionally, the company provides comprehensive eye care products, including lens care solutions, which enhance user satisfaction and ensure sustained demand. Alcon’s revenue model hinges on its ability to deliver cutting-edge products that meet the evolving needs of consumers and professionals alike. Through strategic investments in research and development and a strong distribution network, Alcon perpetually reinforces its market presence, securing its position as a formidable player in the eye care industry.
